News

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
Capital Raised to Support Five Clinical TrialsATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on ...